NASDAQ · FHTX
Foghorn Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FHTX: Nov 4, 2026
Foghorn Therapeutics Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.25.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.23 | $-0.17 | $-0.29 | 5 |
| Dec 2026 | $-0.24 | $-0.18 | $-0.29 | 5 |
| Mar 2027 | $-0.22 | $-0.17 | $-0.27 | 2 |
| Jun 2027 | $-0.22 | $-0.17 | $-0.27 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Quiver Quantitative- Quiver Quantitative · May 22, 7:13 AM EDTFoghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025Foghorn Therapeutics will participate in multiple upcoming biotech conferences, focusing on oncology and gene regulation advancements.
- Quiver Quantitative · May 1, 7:14 AM EDTFoghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of DirectorsFoghorn Therapeutics elects Neil Gallagher and Stuart Duty to its Board, enhancing leadership in oncology drug development.
- Quiver Quantitative · Apr 28, 4:14 PM EDTFoghorn Therapeutics Advances FHD-909 in Phase 1 Trial for SMARCA4 Mutated Cancers with Promising Preclinical Data for Combination TherapiesFoghorn Therapeutics announces Phase 1 trial progress for FHD-909 in SMARCA4 mutated cancers, showcasing promising preclinical data.
- Quiver Quantitative · Mar 6, 4:14 PM ESTFoghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial OutlookFoghorn Therapeutics updates on FHD-909 trial enrollment for NSCLC, financials, and progress on degrader programs.
- Quiver Quantitative · Dec 16, 7:12 AM ESTFoghorn Therapeutics Discontinues Development of FHD-286 for AML, Shifts Focus to Proprietary Pipeline and CollaborationsFoghorn Therapeutics halts FHD-286 development for AML, focusing on proprietary pipeline and Lilly collaboration; strong cash position until 2027.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Foghorn Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.